Department of New Experimental Therapeutics, Early-Phase 1 Drug Development Service at the Kansai Medical University Hospital is honored to be selected to be part of AbbVie’s Phase 1 Partnerships for Excellence in Research (P1PER) network, P1PER is AbbVie’s global network of leading clinical trial centers in oncology, designed to accelerate early development of novel therapies across difficult-to-treat blood cancers and solid tumors. P1PER was created to further advance and accelerate cancer research and foster groundbreaking collaboration and innovation. Our participation reflects a shared commitment to innovation, collaboration, and delivering meaningful progress for patients in need.
Professor Shimizu discussed with Eleni Lagkadinou, MD, PhD, Vice President, Head of Oncology Early Development, AbbVie for furthermore collaboration across KMUH and AbbVie in Chicago IL on May 30, 2025.
Click the link below to learn more about this important partnership and our contribution to the future of cancer care.
